<H1>Chapter DOI: 10.1007/s00105-014-3567-8<br/>Cited-By Count: 3</H1><table border="1" width="30%"><tr><td>Total References</td><td>13</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>13</td></tr><tr><td>BibStructured Count</td><td width="10%">13</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>13</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Fonkem E, Uhlman EJ, Mahadevan A et al (2012) Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 12(10):1207&#8211;1215</td><td><a href=http://dx.doi.org/10.1586/ern.12.111>10.1586/ern.12.111</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11(9):1699&#8211;1707</td><td><a href=http://dx.doi.org/10.1016/0360-3016(85)90223-8>10.1016/0360-3016(85)90223-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Hodi FS, Oble DA, Drappatz J et al (2008) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5(9):557&#8211;561</td><td><a href=http://dx.doi.org/10.1038/ncponc1183>10.1038/ncponc1183</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Di Giacomo AM Ascierto PA, Pilla L et al (2012) Ipilimumab and fotemustinein patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879&#8211;886</td><td><a href=http://dx.doi.org/10.1016/S1470-2045(12)70324-8>10.1016/S1470-2045(12)70324-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Weber JS, Amin A, Minor D et al (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trail. Melanoma Res 21:530&#8211;534</td><td><a href=http://dx.doi.org/10.1097/CMR.0b013e32834d3d88>10.1097/CMR.0b013e32834d3d88</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925&#8211;931</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1112824>10.1056/NEJMoa1112824</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050&#8211;1059</td><td><a href=http://dx.doi.org/10.1038/nm1622>10.1038/nm1622</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Matsumura S, Wang B, Kawashima N et al (2008) Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181:3099&#8211;3107</td><td><a href=http://dx.doi.org/10.4049/jimmunol.181.5.3099>10.4049/jimmunol.181.5.3099</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Demaria S, Pilones KA, Formenti SC et al (2013) Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA4 treatment. Oncoimmunology 2(3):e23127</td><td><a href=http://dx.doi.org/10.4161/onci.23127>10.4161/onci.23127</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Dewan MZ, Galloway AE, Kawashima N et al (2009) Fractionated but not single-dose radiotherapy. Clin Cancer Res 1(15):5379&#8211;5388</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-09-0265>10.1158/1078-0432.CCR-09-0265</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Iversen TZ, Klinge Brimnes M, Nikolajsen K et al (2013) Depletion of T lymphocytes is correlated with response to temazolamide in melanoma patients. Oncoimmunology 2(2):e23288</td><td><a href=http://dx.doi.org/10.4161/onci.23288>10.4161/onci.23288</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295&#8211;307</td><td><a href=http://dx.doi.org/10.1038/nri1806>10.1038/nri1806</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Scherill B, Wang J, Kotapati S et al (2013) Q-Twist analysis comparing ipilimumab/dacarbazine vs. placebo/dacarbazine for patient stage III/IV melanoma. Br J Cancer 109(1):8&#8211;13</td><td><a href=http://dx.doi.org/10.1038/bjc.2013.298>10.1038/bjc.2013.298</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>